COMPASS FINANCIAL MANAGEMENT LLC’s AbbVie ABBV Stock Holding History

COMPASS FINANCIAL MANAGEMENT LLC’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.76M	Buy	+11,160	New	+$2.4M	0.33%	79

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

COMPASS FINANCIAL MANAGEMENT LLC's ABBV Position: Q2 2026 in Review

COMPASS FINANCIAL MANAGEMENT LLC opened a new position in AbbVie (ABBV) in Q2 2026: 11,160 shares worth $2.76M. The stake represents 0.33% of the portfolio and ranks #79 among its holdings.

3,435 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

COMPASS FINANCIAL MANAGEMENT LLC held 11,160 shares of AbbVie worth $2.76M as of Q2 2026.
AbbVie was a new COMPASS FINANCIAL MANAGEMENT LLC position in Q2 2026.
AbbVie made up 0.33% of COMPASS FINANCIAL MANAGEMENT LLC's portfolio in Q2 2026, its #79 holding.
3,435 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on COMPASS FINANCIAL MANAGEMENT LLC's 13F filing for Q2 2026, filed 12 Aug 2026.